Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 5 (2008), Issue 2 (February)

1. Dicentric chromosomes and 20q11.2 amplification in MDS/AML with apparent monosomy 20.
   Cytogenet Genome Res, 119(3): 211-20. [Abstract] [Full-text]
2. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
   J Natl Cancer Inst, 100(3): 184-98. [Abstract] [Full-text]
3. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.
   Genes Chromosomes Cancer, 47(4): 276-87. [Abstract] [Full-text]
4. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
   Genes Chromosomes Cancer, 47(4): 288-98. [Abstract] [Full-text]
5. Glutathione level regulates HNE-induced genotoxicity in human erythroleukemia cells.
   Toxicol Appl Pharmacol, 227(2): 257-64. [Abstract] [Full-text]
6. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
   Eur J Haematol, 80(3): 201-7. [Abstract] [Full-text]
7. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes.
   Eur J Haematol, 80(3): 216-26. [Abstract] [Full-text]
8. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
   Eur J Haematol, 80(3): 208-15. [Abstract] [Full-text]
9. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.
   Clin Infect Dis, 46(6): 878-85. [Abstract] [Full-text]
10. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Cancer, 112(3): 572-80. [Abstract] [Full-text]
11. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Cancer, 112(3): 562-71. [Abstract] [Full-text]
12. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.
    Leuk Lymphoma, 49(3): 543-53. [Abstract] [Full-text]
13. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
    Leuk Lymphoma, 49(3): 524-30. [Abstract] [Full-text]
14. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
    Leuk Lymphoma, 49(3): 517-23. [Abstract] [Full-text]
15. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
    Leuk Lymphoma, 49(3): 508-16. [Abstract] [Full-text]
16. Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences.
    Leuk Lymphoma, 49(3): 495-501. [Abstract] [Full-text]
17. A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia.
    Pediatr Blood Cancer, 50(4): 869-71. [Abstract] [Full-text]
18. Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement.
    Pediatr Blood Cancer, 50(4): 921-3. [Abstract] [Full-text]
19. Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Pediatr Blood Cancer, 50(4): 872-4. [Abstract] [Full-text]
20. Acute promyelocytic leukemia: from highly fatal to highly curable.
    Blood, 111(5): 2505-15. [Abstract] [Full-text]
21. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
    Blood, 111(5): 2589-96. [Abstract] [Full-text]
22. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.
    Blood, 111(5): 2854-65. [Abstract] [Full-text]
23. Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML.
    Blood, 111(5): 2899-903. [Abstract] [Full-text]
24. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
    Blood, 111(5): 2527-37. [Abstract] [Full-text]
25. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
    Blood, 111(5): 2776-84. [Abstract] [Full-text]
26. Current management and challenges of malignant disease in the CNS in paediatric leukaemia.
    Lancet Oncol, 9(3): 257-68. [Abstract] [Full-text]

© 2004-2012 Acute Myeloid Leukemia Research Today. All Rights Reserved.